Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. related to a federal securities class action due to alleged violations of federal securities laws [1] - The complaint alleges that REGENXBIO and its executives made false or misleading statements and failed to disclose material adverse facts regarding the efficacy and safety of its RGX-111 trial study [1] - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 investigational gene therapy for MPS I after a case of neoplasm was reported in a participant [1] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the clinical studies [1] - Following the FDA's announcement, REGENXBIO's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share [1] Group 2 - The deadline for investors to seek the role of lead plaintiff in the class action is April 14, 2026 [1] - Any member of the putative class can move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1] - Faruqi & Faruqi encourages individuals with information regarding REGENXBIO's conduct to contact the firm, including whistleblowers and former employees [1]

KLAR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Klarna Group plc (KLAR) Investors of Securities Class Action Deadline on February 20, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In Klarna To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [Klarna] pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Regist ...

Core Viewpoint - Lake Street has lowered the price target for Aquestive Therapeutics (AQST) to $6 from $8 while maintaining a Buy rating after the company received a Complete Response Letter (CRL) for Anaphylm and plans to resubmit in Q3 [1] Group 1 - The price target adjustment reflects the delay in the approval of Anaphylm [1] - Revenue estimates have been adjusted accordingly due to the CRL received by the company [1]

Core Viewpoint - Aquestive Therapeutics (AQST) received a Complete Response Letter (CRL) for Anaphylm, but the outcome is seen as recoverable with a clear path to approval [1] Group 1: FDA Response - The FDA's prior deficiency letter was anticipated by Leerink analyst Roanna Ruiz, indicating that the CRL was not unexpected [1] - No additional studies beyond those already conducted have been requested by the FDA, which is a positive sign [1] Group 2: Market Reaction - Following the news, shares of AQST increased by over 45%, reaching $4.29 in morning trading [1] Group 3: Future Considerations - The CRL does not raise concerns regarding comparability data or Chemistry, Manufacturing, and Controls (CMC), suggesting manageable studies for resubmission [1] - Potential risks include delays in Anaphylm's U.S. launch and reliance on favorable results from HF testing and PK studies for resubmission [1]

… Last Friday, Aquestive got slapped down by the FDA, and the stock plunged 37% in a single session before losing another 15% this week… Despite the ambiguous slap down from the FDA, Aquestive maintains that all of its engagement with the FDA has been ‘highly collaborative.’ And the management said that since they received the letter, the FDA has repeatedly said the review of Anaphylm remains ongoing. These guys still sound really confident about their drug and their ability to get it approved both here and ...

Market Overview - Stock futures are modestly higher following the December nonfarm payrolls report and ahead of a Supreme Court decision on President Trump's tariff policy [1] - Major indexes have shown resilience early in 2026 after a strong finish to 2025, but gains have faced headwinds due to cooling tech momentum and uncertainty around labor data affecting Federal Reserve policy expectations [1] Sector Performance - Defensive sectors such as energy and mining have demonstrated relative strength, while value-oriented and cyclical areas are gaining attention amid market rotation [2] - Safe-haven assets like gold have seen increased demand as risk sentiment fluctuates [2] Pre-Market Trading - In pre-market trading, S&P 500 futures rose by 0.33%, Nasdaq futures increased by 0.42%, and Dow futures were up by 0.32% [2] Company Movements - Oklo (OKLO) is up 18% after announcing an agreement with Meta Platforms (META) to develop a 1.2 GW power campus in Pike County, Ohio [5] - Vistra (VST) increased by 17% after entering into 20-year purchase power agreements to provide over 2,600 megawatts of zero-carbon energy from three nuclear plants for Meta's operations [5] - Intel (INTC) rose by 2% following President Trump's positive remarks about a meeting with CEO Lip-Bu Tan [5] - Offerpad Solutions (OPAD) surged by 48%, LoanDepot (LDI) increased by 16%, Opendoor Technologies (OPEN) rose by 11%, Rocket Companies (RKT) was up by 6%, and UWM Holdings (UWMC) also increased by 6% [5] - Conversely, Aquestive Therapeutics (AQST) fell by 37% after the FDA identified deficiencies in its Anaphylm NDA, while AXT Inc. (AXTI) dropped by 14% after cutting its Q4 revenue outlook [5]

Group 1 - ARS Pharmaceuticals Inc. stock increased by 18.86% to $13.01 following a negative update regarding its competitor, Aquestive Therapeutics Inc. [5] - The FDA identified deficiencies in Aquestive's Anaphylm's New Drug Application, which delays discussions on labeling and post-marketing commitments [1] - This situation allows ARS Pharmaceuticals to establish its needle-free epinephrine device, neffy, as the only option in the market for the time being [2] Group 2 - ARS Pharmaceuticals filed a petition urging the FDA to delay approval of Aquestive's AQST-109, citing safety and efficacy concerns [3] - The company argues that current data do not sufficiently demonstrate the drug's safety or efficacy for anaphylaxis patients and requests additional studies [4] - Analysts see significant potential for neffy and believe the company is well-funded to support its launch [4]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - Utilities sector shares increased by 1.5%, while health care stocks experienced a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] European Market Trends - European shares were generally higher, with the eurozone's STOXX 600 gaining 0.91%, Spain's IBEX 35 Index rising 0.01%, London's FTSE 100 increasing by 0.85%, Germany's DAX up by 0.43%, and France's CAC 40 rising by 1.23% [6] Asian Market Trends - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61%, Hong Kong's Hang Seng Index up by 0.32%, China's Shanghai Composite rising by 0.92%, while India's BSE Sensex fell by 0.72% [7] Company-Specific Movements - Rich Sparkle Holdings Ltd saw its shares increase by 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares surged by 31% to $8.54 following the appointment of Everett Cunningham as President and CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped by 40% to $3.72 due to an FDA letter identifying deficiencies [9] - Pacira Biosciences Inc shares fell by 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations of 60,000 [10] - The unemployment rate decreased from 4.5% in November to 4.4%, below expectations [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units, while building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0 in January, the highest since September 2025 [10]

Group 1: Market Reactions and Economic Indicators - Stock futures are muted as traders await a Supreme Court ruling on Trump's tariffs and December payrolls data, with S&P 500 futures up 0.1% and Nasdaq 100 contracts up 0.2% [1] - Mortgage stocks surged after President Trump announced a directive for the purchase of $200 billion in mortgage bonds, with LoanDepot (LDI) rising 16% and Rocket Companies (RKT) increasing by 5% [1][4] - The December jobs report and other economic indicators are scheduled for release, including October housing starts and University of Michigan sentiment [1][19] Group 2: Corporate News - Rio Tinto is in discussions to acquire Glencore, potentially creating the world's largest mining company with a combined market value exceeding $200 billion [2] - TSMC reported quarterly sales that surpassed estimates, raising expectations for sustained global AI spending in 2026 [2] - General Motors shares fell after announcing an additional $6 billion in charges related to cutbacks in electric vehicle and battery operations [2] Group 3: Stock Movements and Company Performance - Mag 7 stocks showed mixed performance in premarket trading, with Alphabet up 0.8% and Meta down 0.2% [3] - AXT Inc. saw a 14% decline after disappointing fourth-quarter revenue forecasts due to fewer export control permits from China [4] - Revolution Medicines gained 13% following reports of Merck's interest in acquiring the cancer drugmaker [4] Group 4: Economic Outlook and Market Sentiment - The S&P 500's early-year rally has slowed, with a shift away from AI stocks towards a broader range of tech players and sectors [5] - Traders are preparing for significant risk events, including the payrolls data and the Supreme Court ruling, which may impact global equities [6] - The market is anticipating a mixed reaction to the jobs data, with expectations for nonfarm payrolls to be around 70,000, in line with consensus [8][34]

Core Insights - Avadel Pharmaceuticals plc is focused on developing innovative medicines for sleep disorders, particularly narcolepsy, and operates in a competitive landscape with peers like Eyenovia, Aquestive Therapeutics, Clearside Biomedical, and Intra-Cellular Therapies [1] Financial Performance - Avadel's Return on Invested Capital (ROIC) is 0.86%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 10.91%, indicating inefficiency in capital use [2] - Eyenovia, Inc. has a ROIC of -33.32% and a WACC of 17.12%, resulting in a ROIC to WACC ratio of -1.94 [3] - Aquestive Therapeutics, Inc. shows a ROIC of -69.51% against a WACC of 13.24%, leading to a ROIC to WACC ratio of -5.25 [3] - Clearside Biomedical, Inc. presents a ROIC of -177.13% and a WACC of 18.30%, resulting in a ROIC to WACC ratio of -9.67 [4] - Intra-Cellular Therapies, Inc. has a ROIC of -8.23% and a WACC of 5.90%, with a ROIC to WACC ratio of -1.39, indicating slightly better capital efficiency compared to peers [4] Industry Challenges - The analysis indicates a challenging environment for biopharmaceutical companies, as none are generating sufficient returns to cover their cost of capital, highlighting the need for improved capital efficiency to enhance investor confidence [5]